Click to rate this post!
[Total: 0 Your Rating: 0]You must sign in to vote
How Vivid Genomics is addressing the drug development challenge
Dementia affects more than 50mm people globally, and the numbers are expected to triple in the next 30 years. There are no FDA approved drugs, however, that can cure, slow, or delay the onset of dementia, and more than 150 drugs that have failed clinical trials in the last 20 years.
Why have all of these drugs failed? Drug development is notoriously difficult: the drug needs to target the right biology, it has to be effective for that target, it needs to be given at the right dose (and at the right time), and the right patients need to be selected.
To address the issue, Vivid Genomics is developing products to characterize variation in patients with neurodegenerative disease. The company is doing this by incorporating genetics, clinical and demographic information, and machine learning to provide information about patients to better understand the response in clinical trials and find the right people, at the right time.